文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

含贝达喹啉和德拉马尼的治疗方案在endTB队列中的安全性

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
PubMed 文献 · Clin Infect Dis · 2022-01-01

这项在16国开展的多中心前瞻性观察研究评估了含贝达喹啉和/或德拉马尼的耐多药/利福平耐药结核病(MDR/RR-TB)长疗程方案的安全性,共纳入2296例患者。最常见临床相关特殊关注不良事件(AESI)为周围神经病变(26.4%)、电解质耗竭(26.0%)和听力损失(13.2%)。与利奈唑胺和注射剂相关的不良事件比常归因于贝达喹啉和德拉马尼的事件更常见。

要点

  • 2296例患者中最常见AESI为周围神经病变26.4%、电解质耗竭26.0%、听力损失13.2%。
  • 接受注射剂(N=925)和利奈唑胺(N=1826)暴露者最易发生事件。
  • 与利奈唑胺和注射剂相关的不良事件比常归因于贝达喹啉和德拉马尼的事件更常见。

核心结论

  • 与利奈唑胺和注射剂相关的不良事件比常归因于贝达喹啉和德拉马尼的不良事件更常见。
  • MDR-TB治疗监测和药物疗程应反映药物组合的预期安全性特征。

研究设计与样本

  • 多中心(16个国家)、前瞻性、观察性研究。
  • 报告接受含贝达喹啉和/或德拉马尼的MDR/RR-TB治疗患者中临床相关特殊关注不良事件(AESI)的发生率和频率。
  • AESI预先定义为由贝达喹啉、德拉马尼、利奈唑胺、注射剂和其他常用药物引起的重要事件。
  • 共纳入2296例患者。

主要发现

  • 最常见临床相关AESI为周围神经病变(26.4%)、电解质耗竭(26.0%)和听力损失(13.2%)。
  • 每1000人月治疗中,周围神经病变发生率为21.5(95%CI:19.8-23.2),电解质耗竭为20.7(95%CI:19.1-22.4),听力损失为9.7(95%CI:8.6-10.8)。
  • QT间期延长发生率为2.7%或每1000人月治疗1.8(95%CI:1.4-2.3)。
  • 接受注射剂(N=925)和利奈唑胺(N=1826)者最易在暴露期间发生事件。
  • 听力损失、急性肾衰竭或电解质耗竭在注射剂暴露中发生率为36.8%或每1000人月注射剂暴露72.8(95%CI:66.0-80.0)次。

临床怎么用

  • MDR-TB治疗监测和药物疗程应反映药物组合的预期安全性特征。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens containing bedaquiline and/or delamanid. METHODS: Multicentre (16 countries), prospective, observational study reporting incidence and frequency of clinically relevant adverse events of special interest (AESIs) among patients who received MDR/RR-TB treatment containing bedaquiline and/or delamanid. The AESIs were defined a priori as important events caused by bedaquiline, delamanid, linezolid, injectables, and other commonly used drugs. Occurrence of these events was also reported by exposure to the likely causative agent. RESULTS: Among 2296 patients, the most common clinically relevant AESIs were peripheral neuropathy (26.4%), electrolyte depletion (26.0%), and hearing loss (13.2%) with an incidence per 1000 person months of treatment, 1000 person-months of treatment 21.5 (95% confidence interval [CI]: 19.8-23.2), 20.7 (95% CI: 19.1-22.4), and 9.7 (95% CI: 8.6-10.8), respectively. QT interval was prolonged in 2.7% or 1.8 (95% CI: 1.4-2.3)/1000 person-months of treatment. Patients receiving injectables (N = 925) and linezolid (N = 1826) were most likely to experience events during exposure. Hearing loss, acute renal failure, or electrolyte depletion occurred in 36.8% or 72.8 (95% CI: 66.0-80.0) times/1000 person-months of injectable drug exposure. Peripheral neuropathy, optic neuritis, and/or myelosuppression occurred in 27.8% or 22.8 (95% CI: 20.9-24.8) times/1000 patient-months of linezolid exposure. CONCLUSIONS: AEs often related to linezolid and injectable drugs were more common than those frequently attributed to bedaquiline and delamanid. MDR-TB treatment monitoring and drug durations should reflect expected safety profiles of drug combinations. CLINICAL TRIALS REGISTRATION: NCT02754765.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Hewison C, Khan U, Bastard M, et al. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort. Clin Infect Dis. 2022. PMID: 35028659. doi:10.1093/cid/ciac019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。